Pavlic M, Libiseller K, Grubwieser P, Rabl W
Institute of Legal Medicine, Innsbruck Medical University, Muellerstrabe 44, 6020 Innsbruck, Austria.
Int J Legal Med. 2005 Nov;119(6):378-81. doi: 10.1007/s00414-005-0544-x. Epub 2005 Apr 16.
When testing the Microgenics CEDIA assay for immunological buprenorphine analysis, cross-reactivity between the buprenorphine reagents and opiates was observed at concentrations higher than 120 mg/l morphine, 320 mg/l methadone, 30 mg/l codeine, 60 mg/l dihydrocodeine and 520 mg/l morphine-3-glucuronide. The cross-reactivity with morphine has the greatest impact on routine screening as opiate maintenance therapy in Austria is also performed with slow-release oral morphine. The use of a second cutoff value of 30 mug/l for urine samples that are (immunologically) positive for opiates is therefore suggested, compared to the cutoff value of 5 microg/l proposed by the manufacturer.
在检测用于免疫分析丁丙诺啡的Microgenics CEDIA检测法时,发现丁丙诺啡试剂与阿片类药物之间在高于120mg/l吗啡、320mg/l美沙酮、30mg/l可待因、60mg/l二氢可待因和520mg/l吗啡-3-葡糖苷酸的浓度下存在交叉反应。与吗啡的交叉反应对常规筛查影响最大,因为奥地利的阿片类维持治疗也使用缓释口服吗啡。因此,建议对阿片类药物(免疫)呈阳性的尿液样本采用30μg/l的第二个临界值,而制造商建议的临界值为5μg/l。